Organization
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
5 abstracts
Abstract
Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.Org: Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Department of Radiology, Fudan University Shanghai Cancer Center, Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital,
Abstract
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
Adjuvant chemotherapy guided by an integrated mRNA–lncRNA signature in triple-negative breast cancer (BCTOP-T-A01): A randomized, open-label, multicenter phase 3 trial.Org: Department of Breast Surgery, Fudan University Shanghai Cancer Center and Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Chongqing Cancer Hospital, Chongqing, China, Northern Jiangsu People's Hospital, Yangzhou, China,
Abstract
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shangai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
A phase II clinical trial of prior regimen rechallenge in third- or later-line treatment for patients with metastatic colorectal cancer.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shangai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Fudan University Shanghai Cancer Center, Shanghai, China, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,